The insulin aspart injection co-developed by Tonghua Dongbao and Jianyou Co. has received US FDA approval for marketing. The drug is indicated to improve glycemic control in adult and pediatric patients with diabetes. According to Novo Nordisk's 2025 annual report, its insulin aspart sales in the United States were 7.166 billion Danish kroner, equivalent to approximately 1.126 billion US dollars, and global sales were 15.765 billion Danish kroner, equivalent to approximately 2.477 billion US dollars. This approval marks a significant milestone in the company's internationalization journey. In the first quarter of 2026, Tonghua Dongbao achieved revenue of 748 million yuan and a net profit attributable to the parent company of 127 million yuan.
Tonghua Dongbao Pharmaceutical Co LtdUS FDA approval for its co-developed insulin aspart injection, a regulatory milestone enabling market entry.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd